InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business
InnoSer’s acquisition of remynd’s CRO business further strengthens its neurology platform by integrating specialized neurodegenerative mouse models, expanding its service portfolio for Alzheimer’s and Parkinson’s diseases.
Diepenbeek, Belgium – March 4th – InnoSer, a leading preclinical contract research organization (CRO), is pleased to announce the acquisition of the CRO business unit from remynd, including its well-established neurodegenerative disease mouse models. This strategic acquisition marks a significant step in InnoSer’s commitment to expanding and solidifying its neurology platform, further establishing itself as one of Europe’s premier neurology-focused CROs.
With this acquisition, InnoSer integrates remynd’s expertise and specialized models for neurodegenerative diseases significantly enhancing client access to a more diverse and specialized portfolio of models for Alzheimer’s and Parkinson’s diseases. The well-characterized remynd models, combined with InnoSer’s histology, EEG and behavioral readouts allow for comprehensive behavioral assessments, advanced histopathology, and biomarker analyses, provide a robust offering to accelerate drug development in neurology. The addition of these models expands InnoSer’s current capabilities in epilepsy, neurodevelopmental and neuromuscular disorders, neuroinflammatory conditions, enabling a more comprehensive approach to neurodegenerative research.
“Our ambition is to be the go-to partner for preclinical neurology research in Europe, and this acquisition strengthens our ability to support groundbreaking discoveries in neurodegenerative diseases,” said Kris Motmans, CEO of InnoSer. “By combining remynd’s CRO expertise with InnoSer’s innovative platforms, we offer our clients a seamless and comprehensive pathway from early discovery to preclinical development.”
remynd’s neurodegenerative mouse models are recognized for their high translational value and ability to support clients through to clinical trials. Their direct integration strengthens InnoSer’s capacity to bridge early discovery and clinical application, enhancing disease modeling, preclinical efficacy testing, and neurodegenerative therapy development. With dedicated teams of scientists and advanced facilities, InnoSer is now positioned to provide a full suite of solutions tailored to the complexities of neurodegenerative drug development whilst supporting remynd’s CRO clients to continue their research seamlessly under InnoSer’s management.
“remynd is now fully focused on advancing its drug development programs, with its first-in-class oral treatment for mild-to-moderate Alzheimer’s set to enter clinical trials in the coming months. At the same time, we are very pleased that Innoser will continue to serve the pharma and biotech community with the deep knowledge and expertise on preclinical models for neurodegenerative disease that we developed over the years.” commented Floor Stam, PhD, CEO remynd.
The acquisition reinforces InnoSer’s mission to provide high-quality, science-driven solutions to its global client base. By leveraging the collective expertise of both organizations, InnoSer is set to play an even greater role in accelerating the development of therapies for patients in need.
You can view the full portfolio of models being acquired and now offered by InnoSer using the link below.
About InnoSer
Founded in 2012, InnoSer is an innovative and dynamic CRO supporting the pre-clinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug development journey with well-characterized in vitro and in vivo disease models in addition to general drug development services, allowing to uncover valuable insights into the mode of action, pharmacokinetics, safety, and efficacy of investigational compounds.
Our current operations focus within the later stages of drug-discovery and early preclinical stage. With in vitro and in vivo disease models available for nephrology, immuno-oncology, neurology and cardiometabolic research, we guide our clients through the drug development pipeline using a combination of in-house expertise and disease-specific models. InnoSer enhances these offerings by providing state-of-the-art imaging and digital pathology options, along with facility management and support services, including colony management.
For more information, please contact:
Kris Motmans
CEO, InnoSer
[email protected]
About remynd
remynd is a clinical-stage biotechnology company dedicated to developing first-in-class oral therapeutics for neurodegenerative diseases, including Alzheimer’s disease and Huntington’s disease. By targeting the underlying disease mechanisms, reMYND aims to restore neuronal function and slow disease progression. With a strong commitment to innovation and patient impact, the company advances breakthrough therapies from discovery to clinical development.
For more information, please contact:
Floor Stam
CEO, remynd
[email protected]